The Quantitative Eye: Quibim's AI Platform Unlocks Predictive Power Hidden in Medical Images

The Silicon Review

In the daily practice of modern medicine, radiologists generate vast quantities of imaging data CT scans, MRIs, PET images that contain far more information than the human eye can perceive. A radiologist can identify tumors, measure their size, and note their location, but the subtle textural patterns, shape characteristics, and intensity variations within those images hold predictive insights about disease progression, treatment response, and patient outcomes that remain invisible to even the most trained observer. This gap between the data captured and the insights extracted represents one of the most significant untapped opportunities in precision medicine.

Quibim was founded to close this gap. Born from years of intensive research in imaging biomarkers, the company made its commercial launch in 2021 with a clear mission: to apply artificial intelligence techniques to medical images and unlock the quantitative data hidden within. Headquartered in Spain with a growing international footprint, Quibim has built a cloud-based, tissue-agnostic platform that extracts radiomic features from the world's largest imaging registries. Its technology serves over 220 sites worldwide, drawing on a registry of more than 150,000 de-identified cancer patients and over 100 million de-identified research images. The company's work spans oncology, immunology, neuroscience, and hematology, with more than 350 publications in high-impact journals validating its approach.

The company's revenue model operates on two parallel tracks serving distinct but complementary markets. For healthcare providers, Quibim markets regulatory-cleared software as a medical device through SaaS subscriptions, with products like QP-Prostate, QP-Brain, and QP-Liver integrating directly into clinical PACS workflows to enhance diagnostic accuracy and efficiency. For life sciences partners, including 60% of the top-10 pharmaceutical companies, Quibim enters value-based partnerships that apply its imaging analytics to drug development programs, patient stratification, and clinical trial optimization. This dual model creates diversified, recurring revenue while ensuring that insights flow continuously between clinical practice and pharmaceutical research, enriching both domains.

The Radiomics Platform as a Drug Development Accelerator

Quibim's most significant commercial opportunity lies in its partnerships with biopharmaceutical companies seeking to accelerate and de-risk drug development. In clinical trials, the ability to identify patients most likely to respond to a therapy, monitor treatment effects quantitatively, and detect adverse events early can mean the difference between a successful approval and a costly failure. Quibim's platform extracts imaging biomarkers that predict which patients will respond to immunotherapy, stratify neuroblastoma patients by risk, and forecast metastatic relapse in prostate cancer. For pharmaceutical partners, these capabilities translate directly into faster trials, smaller sample sizes, and higher probability of success. Quibim generates revenue through fee-for-service imaging analytics, milestone-based partnerships, and technology licensing arrangements that align its incentives with client outcomes. With more than 50 active clinical studies and partnerships spanning oncology, immunology, and neuroscience, this life sciences business represents a high-growth, high-margin revenue stream with significant barriers to entry.

The Clinical Product Portfolio for Recurring SaaS Revenue

Quibim has translated its research expertise into a portfolio of regulatory-cleared medical devices that generate recurring revenue through clinical adoption. QP-Prostate automates prostate MRI analysis, providing quantitative information and PI-RADS compliance while seamlessly integrating with existing PACS systems. QP-Brain delivers automated brain volumetry and white matter hyperintensity analysis to support diagnosis of neurological conditions. QP-Liver quantifies fat and iron concentration for comprehensive evaluation of steatosis and iron overload. These products are marketed through SaaS subscriptions to hospitals and imaging centers, creating predictable, recurring revenue with high gross margins. The clinical deployments also generate invaluable real-world data that feeds back into Quibim's research and development, continuously improving algorithm performance and informing new product development. Each new site added to the platform increases the company's data advantage while contributing to recurring revenue growth.

The Data Harmonization Capability as a Strategic Moat

A critical but often overlooked component of Quibim's technology is its ability to harmonize imaging data acquired across different equipment manufacturers, protocols, and institutions. Medical images vary significantly in signal, contrast, and noise depending on the scanner used and the acquisition parameters selected, creating variability that confounds quantitative analysis. Quibim's QP-Insights platform applies standardization algorithms that minimize this variability, enabling meaningful comparison of images acquired across different sites and over time. This harmonization capability is essential for both multi-center clinical trials and real-world evidence studies, and it represents a significant competitive advantage. Pharmaceutical companies conducting global trials cannot afford to have their imaging data rendered incomparable by technical variability; Quibim's platform solves this problem at scale. The capability also strengthens Quibim's data moat; as more diverse images flow through its harmonization pipeline, the platform's algorithms become increasingly robust and valuable.

The Security and Compliance Infrastructure for Enterprise Trust

Operating at the intersection of healthcare and artificial intelligence requires rigorous attention to security, privacy, and regulatory compliance. Quibim has built its operations around enterprise-grade standards, achieving ISO 27001:2022 certification for information security, ISO 13485 certification for quality management, and compliance with HIPAA, GDPR, and Spain's National Security Scheme. All data is encrypted during storage and transmission, processed on Microsoft Azure's secure cloud infrastructure, and handled according to strict access controls and audit trails. This compliance infrastructure enables Quibim to serve the most demanding enterprise clients, including top-tier pharmaceutical companies and major hospital systems, which cannot compromise on data security. It also creates significant barriers to entry for competitors who lack the resources and expertise to achieve and maintain these certifications.

For pharmaceutical companies racing to develop new therapies and healthcare providers striving to deliver precision medicine, Quibim offers a critical capability: the ability to see what has always been hidden in medical images. Its AI-powered platform transforms qualitative observations into quantitative measurements, subjective interpretations into objective biomarkers, and isolated data points into actionable predictions. With a growing footprint across more than 220 sites, partnerships with the world's leading drug developers, and a portfolio of clinical products deployed in routine practice, Quibim is establishing itself as an essential infrastructure for the data-driven future of medicine. Its success reflects a fundamental truth of the precision medicine era: the images already being acquired contain the answers; the challenge is learning to see them.

Dr. Ángel Alberich-Bayarri, CEO & Co-Founder